GlassScriptPhysician profile
Eduardo Valdes
NPI 1831506179
$3,946.88
in general payments reported to CMS, 2019-2025
29 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $752 · 2020: $1,028 · 2021: $652 · 2022: $844 · 2023: $366 · 2024: $38.02 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $669.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $933.72 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $677.36 | 2019-2023 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $541.40 | 2019-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $384.21 | 2021-2025 | |
| Gm Pharmaceuticals, INC. | $300.17 | 2020 | |
| Merck Sharp & Dohme LLC | $119.53 | 2019-2022 | |
| Glaxosmithkline, LLC. | $117.72 | 2019-2023 | Bexsero, Trelegy Ellipta |
| Abbott Laboratories | $117.68 | 2019-2024 | Freestyle Libre |
| Janssen Pharmaceuticals, INC | $82.94 | 2019-2021 | |
| Lilly USA, LLC | $80.80 | 2020-2023 | Emgality, Jardiance |
| Pfizer INC. | $76.90 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.05 | 2022-2023 | Xifaxan |
| Abbvie INC. | $59.76 | 2020-2023 | Vraylar |
| Phadia US INC. | $44.03 | 2021-2023 | Immunocap |
| Genentech USA, INC. | $43.96 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $37.93 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $29.32 | 2022 | |
| Redhill Biopharma INC. | $26.67 | 2020-2021 | |
| Sanofi Pasteur INC. | $25.00 | 2019 | |
| Hologic Sales and Service, LLC | $24.49 | 2020 | |
| Gilead Sciences, INC. | $22.73 | 2019 | |
| Exact Sciences Corporation | $20.92 | 2023 | Cologuard Collection Kit |
| Shield Therapeutics INC | $20.45 | 2023 | Accrufer |
| Dexcom, INC. | $19.51 | 2023 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $16.96 | 2021 | |
| Amgen INC. | $15.58 | 2024 | Otezla, Repatha |
| Horizon Therapeutics Plc | $14.24 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $13.77 | 2020 | |
| Nestle Healthcare Nutrition INC. | $13.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Valdes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.